Secretin is a peptide hormone released mainly by S cells in the lining of the duodenum, the first part of the small intestine. Its principal action is to stimulate the pancreas to secrete fluid rich in bicarbonate, which neutralizes acid arriving from the stomach. Secretin therefore helps establish conditions suitable for intestinal digestion and protects the intestinal lining from excessive acidity. Its discovery in 1902 was a foundational event in the development of endocrinology.
Structure and secretion
Mature human secretin consists of 27 amino acids. It is produced from a larger precursor protein encoded by the SCT gene. It belongs to the secretin–glucagon family of peptide hormones, whose members include glucagon and several other regulatory peptides.
Secretin-producing S cells are enteroendocrine cells: specialized epithelial cells that release hormones in response to conditions within the digestive tract. They are concentrated in the duodenum and also occur farther along the proximal small intestine.
The major physiological stimulus for secretin release is acid entering the duodenum from the stomach. Release increases as duodenal contents become acidic, particularly below approximately pH 4.5. Products of fat digestion can also stimulate secretion. Secretin enters the circulation and reaches target tissues through the bloodstream.
As bicarbonate neutralizes the acid, the stimulus for further secretin release diminishes. This negative-feedback relationship contributes to digestive homeostasis.
Mechanism of action
Secretin binds to the secretin receptor, a member of the class B family of G protein-coupled receptors. Receptor activation stimulates adenylyl cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP). This signaling pathway activates protein kinase A and regulates ion transport across the membranes of secretory cells.
In pancreatic duct cells, the resulting transport of bicarbonate and other ions drives water into the duct lumen. The secretion travels through the pancreatic duct into the duodenum.
The CFTR anion channel and associated bicarbonate transporters participate in this process. Disruption of CFTR function in cystic fibrosis can impair pancreatic fluid and bicarbonate secretion, contributing to duct obstruction and pancreatic damage.
Physiological functions
Pancreatic bicarbonate secretion
Secretin primarily stimulates the ductal component of pancreatic secretion: a relatively large volume of alkaline, bicarbonate-rich fluid. This differs from the enzyme-rich secretion produced principally by pancreatic acinar cells.
Bicarbonate neutralizes gastric acid through reactions that can be represented as:
Neutralization helps protect the duodenal mucosa and provides a more favorable pH for pancreatic digestive enzymes.
Secretin acts together with cholecystokinin and neural signals. Cholecystokinin primarily promotes pancreatic enzyme secretion and gallbladder contraction, whereas secretin primarily promotes fluid and bicarbonate secretion. Their effects can potentiate one another.
Biliary and gastric effects
Secretin also stimulates bicarbonate-rich fluid secretion by cells lining the bile ducts, contributing to the volume and alkalinity of bile.
It participates in feedback mechanisms that restrain gastric acid secretion and gastric emptying when acidic contents enter the intestine. These effects help coordinate delivery of stomach contents with the intestine’s capacity to neutralize and digest them. Gastric regulation nevertheless involves many other hormonal and neural pathways; secretin is not its sole controller.
Discovery and historical significance
In 1902, British physiologists William Bayliss and Ernest Starling investigated how acid in the intestine stimulated pancreatic secretion. Their experiments demonstrated that the response could occur when relevant neural connections had been interrupted. An extract of acid-treated intestinal mucosa, introduced into the circulation, also stimulated pancreatic secretion.
They concluded that the intestinal lining released a chemical messenger carried by the blood, and named it secretin. The finding established that digestive organs could communicate through circulating chemical signals, rather than exclusively through nerves.
Starling introduced the term hormone in 1905. Secretin is commonly described as the first hormone discovered, although observations concerning other internal secretions preceded it; its distinctive historical importance lies in the experimental demonstration of a blood-borne messenger and its role in establishing the hormone concept.
Diagnostic uses
Synthetic human secretin is used as a diagnostic stimulant rather than as a routine replacement treatment.
Pancreatic function testing
Secretin stimulation tests assess the pancreas’s ability to produce bicarbonate-rich fluid. In direct testing, duodenal fluid is collected after secretin administration and analyzed for bicarbonate concentration and, depending on the protocol, other measures of secretion.
These tests can contribute to investigation of pancreatic dysfunction, including that associated with chronic pancreatitis. Results depend on the collection method and testing protocol and are interpreted alongside other findings. A secretory response is not, by itself, a complete assessment of digestive enzyme output or exocrine pancreatic insufficiency.
Secretin-enhanced imaging
Secretin can be administered during magnetic resonance cholangiopancreatography, an application of magnetic resonance imaging. The temporary increase in pancreatic fluid secretion can improve visualization of pancreatic ducts and provide information about fluid passage into the duodenum. This combines anatomical imaging with a limited functional assessment.
Secretin stimulation in suspected gastrinoma
A secretin stimulation test can assist the evaluation of suspected gastrinoma, a gastrin-secreting neuroendocrine tumor associated with Zollinger–Ellison syndrome. In many affected patients, secretin produces a paradoxical rise in blood gastrin.
Interpretation requires attention to baseline gastrin, gastric acidity, acid-suppressing medication, and the testing protocol. The response is not an isolated substitute for the broader diagnostic evaluation.
Limits of therapeutic use
Secretin’s established clinical applications are principally diagnostic. Controlled studies have not demonstrated benefit for the core features of autism spectrum disorder, despite earlier interest based on uncontrolled reports. Its physiological role in digestion does not establish effectiveness as a treatment for unrelated conditions.